期刊文献+

手工免疫组化检测ALK融合基因的可行性

下载PDF
导出
摘要 2021年2月WHO国际癌症研究机构发布的数据显示,我国肺癌的发病数及病死例数均位列中国恶性肿瘤第一位^([1]),其中非小细胞肺癌(non-small cell lung carcinoma,NSCLC)占肺癌80%~85%。研究发现,肺癌的治疗和预后受到肿瘤组织基因突变类型的影响^([2])。
出处 《临床与实验病理学杂志》 CAS 北大核心 2024年第8期881-883,共3页 Chinese Journal of Clinical and Experimental Pathology
  • 相关文献

参考文献7

二级参考文献33

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 [J]. CA: a cancer journal for clinicians, 2012, 620): 10-29.
  • 2Kwak EL, Bang Y J, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer[J]. The New England journal of medicine, 2010, 363(18): 1693-1703.
  • 3Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy [.1]. Science, 2004, 304(5676): 1497-1500.
  • 4Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment[J]. Lancet, 2013, 382(9893): 720-731.
  • 5Bergethon K, Shaw AT, Ou SH, et al. ROSI rearrangements define a unique molecular class of lung cancers [J]. Journal of clinicaloncology: official journal of the American Society of Clinical Oncology, 2012, 30(8): 863-870.
  • 6Rosell R, Karachaliou N, Codony J, et al. A critical question for cancer therapy: what new targets exist? [J]. Translational lung cancer research, 2014, 3(6): 384-388.
  • 7Cancer Genome Atlas Research N. Comprehensive genomic characte- rization of squamous cell lung cancers [J]. Nature, 2012, 489(7417): 519-525.
  • 8Drilon A, Wang L, Hasanovic A, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas [J]. Cancer discovery, 2013, 3(6): 630-635.
  • 9Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours[J]. Nature, 2004, 431 (7008): 525-526.
  • 10Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers [J]. Cell, 2012, 150(6): 1121-1134.

共引文献320

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部